What is the primary reason for this Form 10-K/A filing?

The primary reason for this filing is to amend Exhibit 10.54, a Collaboration and License Agreement with Celltech R&D Limited, by refiling it with reduced redactions. This action was taken after Amgen sought and received guidance from the SEC staff regarding the confidential treatment of certain portions of the agreement.

Does this amendment change Amgen's financial performance for the fiscal year ended December 31, 2012?

No, this amendment is purely administrative and pertains to the disclosure of specific contractual information (Exhibit 10.54). It does not modify or update any of the financial statements or operational disclosures made in the original Form 10-K filing for the year ended December 31, 2012.

What is Exhibit 10.54 about?

Exhibit 10.54 is the Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited, dated May 10, 2002, along with its Amendment No. 1, effective June 9, 2003. This amendment reflects a revised version of this exhibit with less information redacted, as originally requested by Amgen for confidential treatment.

Are there any new financial results or operational updates in this filing?

No, this filing is not intended to provide new financial results or operational updates. It is solely an amendment to correct the redaction level of a specific exhibit related to a prior agreement. All other disclosures from the original Form 10-K remain as filed.

AMGN 10-K FY2012 Annual Report — Revenue, Net Income, EPS

Summary

This filing is an amendment (10-K/A) to Amgen Inc.'s previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The amendment specifically pertains to Exhibit 10.54, a Collaboration and License Agreement between Amgen and Celltech R&D Limited. The company sought confidential treatment for portions of this exhibit and is refiling it with reduced redactions following discussions with the SEC staff. This amendment does not alter other financial information or disclosures from the original 10-K and is primarily administrative in nature, re-establishing the exhibit with revised confidentiality status.

Financial Highlights

55 data points

Beta

Revenue

$17.27B

0.8% Gross Margin

Net Income

$4.34B

0.3% Net Margin

EPS (Diluted)

$5.52

Total Assets

$54.30B

Cash & Equivalents

$3.26B

Free Cash Flow

$5.19B

Financial Statements

Beta

Revenue	$17.27B
Cost of Revenue	$3.20B
Gross Profit	$14.07B
SG&A Expenses	$4.81B
Operating Expenses	$11.69B
Operating Income	$5.58B
Interest Expense	$1.05B
Net Income	$4.34B
EPS (Basic)	$5.61
EPS (Diluted)	$5.52
Shares Outstanding (Basic)	775.00M
Shares Outstanding (Diluted)	787.00M

Key Highlights

1This is an Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2012.
2The sole purpose of this amendment is to refile Exhibit 10.54, a Collaboration and License Agreement with Celltech R&D Limited, with less redacted information.
3The amendment addresses the confidential treatment of specific portions of Exhibit 10.54, following SEC staff correspondence.
4This filing does not amend any other information or financial statements presented in the original Form 10-K.
5New certifications from the CEO and CFO are included as required by Rule 13a-14(a).
6The amendment supersedes the previously filed version of Exhibit 10.54.
7Amgen Inc. is identified as a large accelerated filer.

AMGEN INC Annual Report (Amendment), Year Ended Dec 31, 2012

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions